COMPASS PATHWAYS PLC Operating Expenses
COMPASS PATHWAYS PLC (CMPS) reported Operating Expenses of $52.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- COMPASS PATHWAYS PLC operating expenses for the quarter ending 2026-06-30 was $52.37M, a 21.99% increase year-over-year.
- COMPASS PATHWAYS PLC operating expenses for the quarter ending 2026-03-31 was $42.90M, a 13.53% decline year-over-year.
- COMPASS PATHWAYS PLC operating expenses for the quarter ending 2025-12-31 was $45.95M, a 5.09% decline year-over-year.
- COMPASS PATHWAYS PLC operating expenses for the quarter ending 2025-09-30 was $40.54M, a 15.37% decline year-over-year.
- COMPASS PATHWAYS PLC operating expenses for fiscal 2025 was $179.04M, a 0.47% increase from fiscal 2024.
- COMPASS PATHWAYS PLC operating expenses for fiscal 2024 was $178.21M, a 30.15% increase from fiscal 2023.
- COMPASS PATHWAYS PLC operating expenses for fiscal 2023 was $136.92M, a 24.02% increase from fiscal 2022.
- COMPASS PATHWAYS PLC operating expenses for fiscal 2022 was $110.40M, a 32.66% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.37M 10-Q · filed 2026-08-05 | $95.28M 10-Q · filed 2026-08-05 | $141.23M derived: sum of 3 quarters · filed 2026-08-05 | $181.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $42.90M 10-Q · filed 2026-05-13 | $88.86M derived: sum of 2 quarters · filed 2026-05-13 | $129.39M derived: sum of 3 quarters · filed 2026-05-13 | $172.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $45.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $86.49M derived: sum of 2 quarters · filed 2026-03-24 | $129.42M derived: sum of 3 quarters · filed 2026-08-05 | $179.04M 10-K · filed 2026-03-24 |
| 2025-09-30 | $40.54M 10-Q · filed 2025-11-04 | $83.47M derived: sum of 2 quarters · filed 2026-08-05 | $133.09M 10-Q · filed 2025-11-04 | $181.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $42.93M 10-Q · filed 2026-08-05 | $92.55M 10-Q · filed 2026-08-05 | $140.96M derived: sum of 3 quarters · filed 2026-08-05 | $188.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $49.62M 10-Q · filed 2026-05-13 | $98.03M derived: sum of 2 quarters · filed 2026-05-13 | $145.93M derived: sum of 3 quarters · filed 2026-05-13 | $189.25M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $48.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $96.31M derived: sum of 2 quarters · filed 2026-03-24 | $139.63M derived: sum of 3 quarters · filed 2026-03-24 | $178.21M 10-K · filed 2026-03-24 |
| 2024-09-30 | $47.90M 10-Q · filed 2025-11-04 | $91.22M derived: sum of 2 quarters · filed 2025-11-04 | $129.79M 10-Q · filed 2025-11-04 | $168.20M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $43.32M 10-Q · filed 2025-07-31 | $81.89M 10-Q · filed 2025-07-31 | $120.30M derived: sum of 3 quarters · filed 2025-07-31 | $154.36M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $38.57M 10-Q · filed 2025-05-08 | $76.98M derived: sum of 2 quarters · filed 2025-05-08 | $111.04M derived: sum of 3 quarters · filed 2025-05-08 | $143.70M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $38.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $72.47M derived: sum of 2 quarters · filed 2025-02-27 | $105.13M derived: sum of 3 quarters · filed 2025-02-27 | $136.92M 10-K · filed 2025-02-27 |
| 2023-09-30 | $34.06M 10-Q · filed 2024-10-31 | $66.73M derived: sum of 2 quarters · filed 2024-10-31 | $98.51M 10-Q · filed 2024-10-31 | $130.71M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $32.66M 10-Q · filed 2024-08-01 | $64.45M 10-Q · filed 2024-08-01 | $96.64M derived: sum of 3 quarters · filed 2024-08-01 | $122.18M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $31.79M 10-Q · filed 2024-05-08 | $63.98M derived: sum of 2 quarters · filed 2024-05-08 | $89.52M derived: sum of 3 quarters · filed 2024-05-08 | $116.77M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $32.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $57.73M derived: sum of 2 quarters · filed 2024-02-29 | $84.98M derived: sum of 3 quarters · filed 2024-02-29 | $110.40M 10-K · filed 2024-02-29 |
| 2022-09-30 | $25.54M 10-Q · filed 2023-11-02 | $52.79M derived: sum of 2 quarters · filed 2023-11-02 | $78.21M 10-Q · filed 2023-11-02 | $106.53M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $27.26M 10-Q · filed 2023-08-03 | $52.68M 10-Q · filed 2023-08-03 | $81.00M derived: sum of 3 quarters · filed 2024-02-29 | $102.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $25.42M 10-Q · filed 2023-05-11 | $53.74M derived: sum of 2 quarters · filed 2024-02-29 | $75.51M derived: sum of 3 quarters · filed 2024-02-29 | $95.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $50.09M derived: sum of 2 quarters · filed 2024-02-29 | $69.62M derived: sum of 3 quarters · filed 2024-02-29 | $83.22M 10-K · filed 2024-02-29 |
| 2021-09-30 | $21.77M 10-Q · filed 2022-11-03 | $41.30M derived: sum of 2 quarters · filed 2022-11-03 | $54.90M 10-Q · filed 2022-11-03 | $66.42M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $19.53M 10-Q · filed 2022-08-04 | $33.13M 10-Q · filed 2022-08-04 | $44.65M derived: sum of 3 quarters · filed 2023-02-28 | $58.13M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $13.60M 10-Q · filed 2022-05-10 | $25.12M derived: sum of 2 quarters · filed 2023-02-28 | $38.60M derived: sum of 3 quarters · filed 2023-02-28 | $56.29M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $11.52M derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | $25.00M derived: sum of 2 quarters · filed 2023-02-28 | $42.69M derived: sum of 3 quarters · filed 2023-02-28 | $51.39M 10-K · filed 2023-02-28 |
| 2020-09-30 | $13.48M 6-K · filed 2021-11-09 | $31.17M derived: sum of 2 quarters · filed 2021-11-09 | $39.87M 6-K · filed 2021-11-09 | |
| 2020-06-30 | $17.69M 6-K · filed 2021-08-11 | $26.39M 6-K · filed 2021-08-11 | ||
| 2019-12-31 | $21.18M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |